WO2017124016A3 - Compositions and methods for internalizing pro-labeled molecules into targeted cells and transforming them in situ into labeled molecules - Google Patents

Compositions and methods for internalizing pro-labeled molecules into targeted cells and transforming them in situ into labeled molecules Download PDF

Info

Publication number
WO2017124016A3
WO2017124016A3 PCT/US2017/013531 US2017013531W WO2017124016A3 WO 2017124016 A3 WO2017124016 A3 WO 2017124016A3 US 2017013531 W US2017013531 W US 2017013531W WO 2017124016 A3 WO2017124016 A3 WO 2017124016A3
Authority
WO
WIPO (PCT)
Prior art keywords
labeled molecules
compositions
methods
internalizing
transforming
Prior art date
Application number
PCT/US2017/013531
Other languages
French (fr)
Other versions
WO2017124016A2 (en
Inventor
Gerald F. SWISS
Robert W. MORIARTY
Richard Pariza
Craig KESHISHIAN
David White
Original Assignee
Isi Life Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/042,103 external-priority patent/US20170234878A1/en
Application filed by Isi Life Sciences, Inc. filed Critical Isi Life Sciences, Inc.
Priority to US15/655,664 priority Critical patent/US20180036312A1/en
Priority to PCT/US2017/043141 priority patent/WO2018026538A1/en
Priority to EP17837395.7A priority patent/EP3493851A4/en
Publication of WO2017124016A2 publication Critical patent/WO2017124016A2/en
Publication of WO2017124016A3 publication Critical patent/WO2017124016A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B11/00Diaryl- or thriarylmethane dyes
    • C09B11/04Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
    • C09B11/10Amino derivatives of triarylmethanes
    • C09B11/24Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed are compositions and methods for assessing the presence of target cell, such as tumor cells amongst normal cells.
PCT/US2017/013531 2016-01-15 2017-01-13 Compositions and methods for internalizing pro-labeled molecules into targeted cells and transforming them in situ into labeled molecules WO2017124016A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/655,664 US20180036312A1 (en) 2016-08-02 2017-07-20 Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
PCT/US2017/043141 WO2018026538A1 (en) 2016-08-02 2017-07-20 Novel scaffolds for intracellular compound delivery for the detection of cancer cells
EP17837395.7A EP3493851A4 (en) 2016-08-02 2017-07-20 Novel scaffolds for intracellular compound delivery for the detection of cancer cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662279596P 2016-01-15 2016-01-15
US62/279,596 2016-01-15
US15/042,103 2016-02-11
US15/042,103 US20170234878A1 (en) 2016-02-11 2016-02-11 Compositions for detecting cancer cells on a cellular surface

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/595,920 Continuation-In-Part US10239891B2 (en) 2016-08-02 2017-05-15 Compositions to detect remnant cancer cells

Publications (2)

Publication Number Publication Date
WO2017124016A2 WO2017124016A2 (en) 2017-07-20
WO2017124016A3 true WO2017124016A3 (en) 2017-10-12

Family

ID=59311484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/013531 WO2017124016A2 (en) 2016-01-15 2017-01-13 Compositions and methods for internalizing pro-labeled molecules into targeted cells and transforming them in situ into labeled molecules

Country Status (1)

Country Link
WO (1) WO2017124016A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3493851A4 (en) * 2016-08-02 2020-06-24 ISI Life Sciences, Inc. Novel scaffolds for intracellular compound delivery for the detection of cancer cells
WO2018026965A1 (en) * 2016-08-02 2018-02-08 Isi Life Sciences, Inc. Compositions and methods for detecting cancer cells in a tissue sample

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455268B1 (en) * 1999-11-05 2002-09-24 Iconix Pharmaceuticals Inc. Hydrolytic enzyme substrates and assay method
US6875850B2 (en) * 2000-09-08 2005-04-05 Roche Diagnostics Operations, Inc. Reagent for labelling nucleic acids
US20130344002A1 (en) * 2002-02-07 2013-12-26 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20140005141A1 (en) * 2006-03-07 2014-01-02 Bio-Technology General (Israel) Ltd. Hydrazido derivatives of hyaluronic acid
US20140227297A1 (en) * 2013-02-08 2014-08-14 The Regents Of The University Of Michigan Targeted theranostics
US20150057433A1 (en) * 2012-03-26 2015-02-26 The Regents Of The University Of California Preparation of functionalized polypeptides, peptides, and proteins by alkylation of thioether groups

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455268B1 (en) * 1999-11-05 2002-09-24 Iconix Pharmaceuticals Inc. Hydrolytic enzyme substrates and assay method
US6875850B2 (en) * 2000-09-08 2005-04-05 Roche Diagnostics Operations, Inc. Reagent for labelling nucleic acids
US20130344002A1 (en) * 2002-02-07 2013-12-26 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20140005141A1 (en) * 2006-03-07 2014-01-02 Bio-Technology General (Israel) Ltd. Hydrazido derivatives of hyaluronic acid
US20150057433A1 (en) * 2012-03-26 2015-02-26 The Regents Of The University Of California Preparation of functionalized polypeptides, peptides, and proteins by alkylation of thioether groups
US20140227297A1 (en) * 2013-02-08 2014-08-14 The Regents Of The University Of Michigan Targeted theranostics

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABBASI ET AL.: "Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and In Vitro Assessment", JOURNAL OF DRUG DELIVER Y, 2012, pages 1 - 8, XP055436901 *
DATABASE Pubchem [O] 18 December 2015 (2015-12-18), XP055437010, Database accession no. 101839416 *
DATABASE Pubchem [O] 26 December 2015 (2015-12-26), XP055436903, Database accession no. 102433897 *
DATABASE Pubchem [O] 8 August 2005 (2005-08-08), XP055437009, Database accession no. 81743 *
OGAWA ET AL.: "Fluorophore-Quencher Based Activatable Targeted Optical Probes for Detecting in Vivo Cancer Metastases", MOLECULAR PHARACEUTICS., vol. 6, 21 January 2009 (2009-01-21), pages 386 - 395, XP055320621 *
ROELANTS ET AL.: "Use of fluorescein isothiocyanate-human serum albumin for the intravesical photodiagnosis of non-muscle-invasive bladder cancer: an in vitro study using multicellular spheroids composed of normal human urothelial and urothelial cell carcinoma cell lines", BJU INTERNATIONAL, vol. 108, 13 December 2010 (2010-12-13), pages 455 - 459, XP055436893 *
URANO ET AL.: "Evolution of Fluorescein as a Platform for Finely Tunable Fluorescence Probes", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 127, 10 March 2005 (2005-03-10), pages 4888 - 4894, XP002481573 *

Also Published As

Publication number Publication date
WO2017124016A2 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
WO2016083613A3 (en) Culture medium
BR112018005937A2 (en) affinity oligonucleotide conjugates and uses of these
WO2014026032A3 (en) Increasing dynamic range for identifying multiple epitopes in cells
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
WO2018109170A3 (en) Il-11ra antibodies
WO2016057951A3 (en) Crispr oligonucleotides and gene editing
EP3280739A4 (en) Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2015112534A3 (en) Compositions and methods for modulating and redirecting immune responses
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
WO2015069682A3 (en) Precise microbiota engineering at the cellular level
WO2016073789A3 (en) Anti-fgfr2/3 antibodies and methods using same
SG10201803042PA (en) Anti-tim-3 antibodies
WO2015151078A3 (en) Hydrophilic linkers for conjugation
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
EP3252172A3 (en) Fast hybridization for next generation sequencing target enrichment
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
WO2016054615A3 (en) Targeted augmentation of nuclear gene output
WO2015161054A3 (en) Methods and systems for nucleic acid amplification
WO2014039718A8 (en) Methods for discovering therapeutic targets
WO2015187825A3 (en) Compositions and methods for modulating dysferlin expression
WO2013188469A3 (en) Pathways characterization of cells
WO2015149034A3 (en) Gene fusions and gene variants associated with cancer
WO2015077657A3 (en) Stat3 inhibitors and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17739089

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17739089

Country of ref document: EP

Kind code of ref document: A2